SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. today announced it has rebranded as Genetix Biotherapeutics Inc., returning to its foundational roots. Genetix, now strengthened both financially and operationally, is significantly better positioned to harness its decades of scientific innovation and extensive clinical data from hundreds of treated patients to more effectively deliver life-changing genetic therapies. The recently appointed Genetix management team, led by CEO David Meek, is.
Brossard, Québec--(Newsfile Corp. - September 11, 2025) - Mines D'Or Orbec Inc. (TSXV: BLUE) (the "Company") is pleased to announce preliminary results from the inaugural seven-hole drill program (four holes being reported here) spaced over a wide distance of about 2.5 km at the Lac Bernard Sud anomaly located at its 100% owned Muus Property within the Chibougamau, Quebec area of the Abitibi Greenstone Belt. The next batch of drill hole assays from Lac Bernard Sud (holes MUUS25-20, MUUS25-24, and MUUS25-25) plus assays from surface sampling undertaken in late summer at a separate area of the Muus Property located 15 km to the east of the Lac Bernard Sud area are expected in the coming weeks.
Brossard, Québec--(Newsfile Corp. - September 5, 2025) - Mines D'Or Orbec Inc. (TSXV: BLUE) (OTCQB: BLTMF) (the "Company" or "Orbec") announces that it has entered into a debt settlement agreement with a former executive of the Company to settle outstanding indebtedness with respect for severance payments owed in the amount of $76,325 by agreeing to issue 150,000 common shares of the Company at deemed price of $0.509 per share. The Board of Directors of the Company has determined that it is in the best interests of the Company to settle the outstanding debt through the issuance of common shares in order to preserve the Company's cash for ongoing operations.
Brossard, Quebec--(Newsfile Corp. - August 11, 2025) - Mines D'Or Orbec Inc. (TSXV: BLUE) (OTC Pink: BLTMF) ("Orbec" or the "Company") is pleased to announce the appointment of Mr. Jean-David Moore to an advisory role within the Company.
Brossard, Quebec--(Newsfile Corp. - July 14, 2025) - Mines d'Or Orbec Inc. (TSXV: BLUE) (OTC Pink: BLTMF) is pleased to announce the successful completion of its 2,000+ metre spring 2025 drilling campaign at its 100% owned Muus property, located in Quebec's Abitibi Greenstone Belt. All assays are pending and are expected to be received from the independent laboratory in approximately 6 weeks.
June Occupancy Shows Continued Momentum in Execution of Clear, Compelling and Effective Strategy Set by Recently Refreshed, Fit-for-Purpose Board Election of Even a Single Ortelius Nominee Would Risk Compromising Brookdale's Strong Forward Momentum NASHVILLE, Tenn. , July 8, 2025 /PRNewswire/ -- Brookdale Senior Living Inc. (NYSE: BKD) ("Brookdale" or the "Company") today reminds all Brookdale shareholders to vote the BLUE proxy card "FOR" ONLY Brookdale's eight superior and highly qualified director nominees in advance of the Company's upcoming 2025 Annual Meeting of Stockholders, scheduled to be held on July 11, 2025.
Brossard, Quebec--(Newsfile Corp. - June 9, 2025) - Further to its news release dated April 24, 2025, Mines D'Or Orbec Inc. (TSXV: BLUE) ("Orbec" or the "Company") is pleased to announce that it has completed the second and final tranche of its non-brokered private placement consisting of the sale of 8,600,000 units (the "Units") at a price of $0.05 per Unit, for aggregate gross proceeds of $430,000 (the "Offering"). Each Unit was comprised of one common share in the capital of the Company (a "Share") and one-half of one Share purchase warrant (each whole warrant, a "Warrant").
SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio (NASDAQ: BLUE) (“bluebird”), a pioneer in gene therapies for severe genetic diseases, today announced the completion of its sale to funds managed by global investment firms Carlyle (NASDAQ: CG) and SK Capital Partners, LP (“SK Capital”). With the closing of the transaction, bluebird's common stock has ceased trading and will no longer be publicly listed. Carlyle and SK Capital have provided significant primary capital to support and scale bluebir.
WASHINGTON & NEW YORK--(BUSINESS WIRE)--Carlyle (NASDAQ: CG) (“Carlyle”), SK Capital Partners, LP (“SK Capital”) and Beacon Parent Holdings, L.P. (“Parent”) today announced that the tender offer commenced on March 7, 2025 to acquire all of the outstanding common stock of bluebird bio, Inc. (NASDAQ: BLUE) (“bluebird”) for either (x) $3.00 per share in cash and a contingent value right per share, entitling the holder to a payment of $6.84 in cash per contingent value right (“CVR”) if bluebird's c.
SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (NASDAQ: BLUE) (“bluebird” or “the Company”) today reminds all stockholders to promptly tender their shares into the tender offer by Carlyle and SK Capital to purchase all outstanding shares of bluebird common stock by 11:59 p.m. Eastern on May 29, 2025. Stockholders that hold shares of bluebird through a broker or other nominee may be subject to a processing cutoff that is prior to the tender deadline, so it is important to act now. Additi.
